424 related articles for article (PubMed ID: 3001499)
21. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells.
Balzarini J; Degrève B; Andrei G; Neyts J; Sandvold M; Myhren F; de Clercq E
Gene Ther; 1998 Mar; 5(3):419-26. PubMed ID: 9614564
[TBL] [Abstract][Full Text] [Related]
22. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
23. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.
Yokota T; Konno K; Shigeta S; Verbruggen A; De Clercq E
Mol Pharmacol; 1987 May; 31(5):493-9. PubMed ID: 3033468
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of the carbocyclic analogue of (E)-5-(2-iodovinyl)-2'-deoxyuridine in herpes simplex virus-infected cells. Incorporation of C-IVDU into DNA.
De Clercq E; Bernaerts R; Balzarini J; Herdewijn P; Verbruggen A
J Biol Chem; 1985 Sep; 260(19):10621-8. PubMed ID: 2993282
[TBL] [Abstract][Full Text] [Related]
26. Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse cells.
Bubley G; Crumpacker C; De Clercq E; Schnipper L
Virology; 1983 Sep; 129(2):490-2. PubMed ID: 6312685
[TBL] [Abstract][Full Text] [Related]
27. Differential metabolism of (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU) by equine herpesvirus type 1- and herpes simplex virus-infected cells.
Kit S; Ichimura H; De Clercq E
Antiviral Res; 1987 Aug; 8(1):41-51. PubMed ID: 2825591
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line.
Balzarini J; De Clercq E; Ayusawa D; Seno T
Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):19-28. PubMed ID: 3990443
[TBL] [Abstract][Full Text] [Related]
29. 5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
Cristofoli WA; Wiebe LI; De Clercq E; Andrei G; Snoeck R; Balzarini J; Knaus EE
J Med Chem; 2007 Jun; 50(12):2851-7. PubMed ID: 17518459
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
Herdewijn P; De Clercq E; Balzarini J; Vanderhaeghe H
J Med Chem; 1985 May; 28(5):550-5. PubMed ID: 2985782
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Wilber BA; Docherty JJ
J Gen Virol; 1994 Jul; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
[TBL] [Abstract][Full Text] [Related]
32. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
Degrève B; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2001 Feb; 59(2):285-93. PubMed ID: 11160865
[TBL] [Abstract][Full Text] [Related]
33. Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.
Wildner O; Blaese RM; Candotti F
Cancer Res; 1999 Oct; 59(20):5233-8. PubMed ID: 10537302
[TBL] [Abstract][Full Text] [Related]
34. Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase.
De Clercq E; Bères J; Bentrude WG
Mol Pharmacol; 1987 Aug; 32(1):286-92. PubMed ID: 3039343
[TBL] [Abstract][Full Text] [Related]
35. The cytostatic activity of 5-(1-azidovinyl)-2'-deoxyuridine (AzVDU) against herpes simplex virus thymidine kinase gene-transfected FM3A cells is due to inhibition of thymidylate synthase and enhanced by UV light (lambda = 254 nm) exposure.
Balzarini J; Andrei G; Kumar R; Knaus EE; Wiebe LI; De Clercq E
FEBS Lett; 1995 Oct; 373(1):41-4. PubMed ID: 7589430
[TBL] [Abstract][Full Text] [Related]
36. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents.
Kim JH; Kim SH; Kolozsvary A; Brown SL; Kim OB; Freytag SO
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):861-8. PubMed ID: 7591895
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of cytostatic action of novel 5-(thien-2-yl)- and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of herpes simplex virus.
Bohman C; Balzarini J; Wigerinck P; Van Aerschot A; Herdewijn P; De Clercq E
J Biol Chem; 1994 Mar; 269(11):8036-43. PubMed ID: 8132526
[TBL] [Abstract][Full Text] [Related]
38. Herpes simplex virus type 1 that exhibits herpes simplex virus type 2 sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Docherty JJ; Dobson AT; Trimble JJ; Jennings BA
Intervirology; 1991; 32(5):308-15. PubMed ID: 1657822
[TBL] [Abstract][Full Text] [Related]
39. Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses.
Meerbach A; Meier C; Sauerbrei A; Meckel HM; Wutzler P
Int J Antimicrob Agents; 2006 May; 27(5):423-30. PubMed ID: 16621459
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8.
Tomicic MT; Friedrichs C; Christmann M; Wutzler P; Thust R; Kaina B
Mol Pharmacol; 2003 Feb; 63(2):439-49. PubMed ID: 12527816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
